These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Quantitative Imaging of Cerebral Thromboemboli In Vivo: The Effects of Tissue-Type Plasminogen Activator. Kim DE; Kim JY; Schellingerhout D; Ryu JH; Lee SK; Jeon S; Lee JS; Kim J; Jang HJ; Park JE; Kim EJ; Kwon IC; Ahn CH; Nahrendorf M; Kim K Stroke; 2017 May; 48(5):1376-1385. PubMed ID: 28432262 [TBL] [Abstract][Full Text] [Related]
25. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303 [TBL] [Abstract][Full Text] [Related]
26. In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke. Yang Y; Gu B; Xu XY Comput Biol Med; 2024 Mar; 171():108141. PubMed ID: 38367449 [TBL] [Abstract][Full Text] [Related]
27. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172 [TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis. Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380 [TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator-coated nanobubbles targeting cellbound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy. Macor P; Durigutto P; Argenziano M; Smith-Jackson K; Capolla S; Di Leonardo V; Marchbank K; Tolva VS; Semeraro F; Ammollo CT; Colucci M; Cavalli R; Meroni P; Tedesco F Haematologica; 2023 Jul; 108(7):1861-1872. PubMed ID: 36172817 [TBL] [Abstract][Full Text] [Related]
31. Endothelial dysfunction after arterial thrombosis is ameliorated by L-arginine in combination with thrombolysis. Davis MR; Ortegon DP; Kerby JD; Ignarro LJ; Kashyap VS J Vasc Interv Radiol; 2003 Feb; 14(2 Pt 1):233-9. PubMed ID: 12582192 [TBL] [Abstract][Full Text] [Related]
32. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Boulaftali Y; Lamrani L; Rouzaud MC; Loyau S; Jandrot-Perrus M; Bouton MC; Ho-Tin-Noé B Thromb Haemost; 2012 May; 107(5):962-71. PubMed ID: 22552380 [TBL] [Abstract][Full Text] [Related]
33. Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research. Hua X; Liu P; Gao YH; Tan KB; Zhou LN; Liu Z; Li X; Zhou SW; Gao YJ J Thromb Thrombolysis; 2010 Jul; 30(1):29-35. PubMed ID: 20155435 [TBL] [Abstract][Full Text] [Related]
34. ADAMTS13 exerts a thrombolytic effect in microcirculation. Crescente M; Thomas GM; Demers M; Voorhees JR; Wong SL; Ho-Tin-Noé B; Wagner DD Thromb Haemost; 2012 Sep; 108(3):527-32. PubMed ID: 22782575 [TBL] [Abstract][Full Text] [Related]
35. A novel hollow and perforated flexible wire allows the safe and effective local application of thrombolytic therapy in a mouse model of deep vein thrombosis. Witsch T; Mauler M; Herr N; Stallmann D; Bode C; Hehrlein C; Duerschmied D J Thromb Thrombolysis; 2014 May; 37(4):450-4. PubMed ID: 24163054 [TBL] [Abstract][Full Text] [Related]
36. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Laing ST; Moody MR; Kim H; Smulevitz B; Huang SL; Holland CK; McPherson DD; Klegerman ME Thromb Res; 2012 Oct; 130(4):629-35. PubMed ID: 22133272 [TBL] [Abstract][Full Text] [Related]
37. Multiphysics Modelling and Simulation of Thrombolysis via Activated Platelet-Targeted Nanomedicine. Gu B; Huang Y; Manchester EL; Hughes AD; Thom SAM; Chen R; Xu XY Pharm Res; 2022 Jan; 39(1):41-56. PubMed ID: 35044591 [TBL] [Abstract][Full Text] [Related]
38. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke. Ma H; Jiang Z; Xu J; Liu J; Guo ZN Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820 [TBL] [Abstract][Full Text] [Related]
39. Preparation and Properties of Thrombus-Targeted Urokinase/Multi-Walled Carbon Nanotubes (MWCNTs)-Chitosan (CS)-RGD Drug Delivery System. Zhang R; Luo S; Hao LK; Jiang YY; Gao Y; Zhang NN; Zhang XC; Song YM J Biomed Nanotechnol; 2021 Sep; 17(9):1711-1725. PubMed ID: 34688316 [TBL] [Abstract][Full Text] [Related]
40. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent. Chang LH; Chuang EY; Cheng TM; Lin C; Shih CM; Wu AT; Jheng PR; Lu HY; Shih CC; Mi FL Acta Biomater; 2021 Oct; 134():686-701. PubMed ID: 34358695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]